Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 8/20 | 0.37 |
| ▸ | RXRA | P19793 | 8/20 | 0.37 |
| ▸ | RXRG | P48443 | 4/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.32 |
| ▸ | MPL | P40238 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462828 | 0.86 | ADORA2A (0.36) | FFAR4HTR1ADRD2DRD4 | |
| SCHEMBL4456610 | 0.78 | FFAR4 (0.40) | RXRBRXRARXRGFFAR4MPL | |
| SCHEMBL6769067 | 0.73 | MCL1 (0.35) | DRD2 | |
| SCHEMBL10475874 | 0.72 | GRM1 (0.35) | — | |
| SCHEMBL4458384 | 0.72 | GRM1 (0.54) | — | |
| SCHEMBL4153075 | 0.70 | CHRNB2 (0.39) | — | |
| SCHEMBL4451812 | 0.70 | FFAR4 (0.41) | RXRBRXRARXRGFFAR4HTR1A | |
| SCHEMBL3034674 | 0.70 | MAPT (0.40) | RXRBRXRA | |
| SCHEMBL13959305 | 0.68 | HTR1A (0.36) | RXRBRXRAHTR1ADRD2DRD4 | |
| SCHEMBL4456613 | 0.66 | GPR119 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | CXCR3, CXCR1, CXCR5 | RXRB 139/4885RXRA 202/4885RXRG 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.